作者
Robert Pirker, Jose R Pereira, Joachim Von Pawel, Maciej Krzakowski, Rodryg Ramlau, Keunchil Park, Filippo De Marinis, Wilfried EE Eberhardt, Luis Paz-Ares, Stephan Störkel, Karl-Maria Schumacher, Anja Von Heydebreck, Ilhan Celik, Kenneth J O'Byrne
发表日期
2012/1/1
期刊
The lancet oncology
卷号
13
期号
1
页码范围
33-42
出版商
Elsevier
简介
Background
Findings from the phase 3 First-Line ErbituX in lung cancer (FLEX) study showed that the addition of cetuximab to first-line chemotherapy significantly improved overall survival compared with chemotherapy alone (hazard ratio [HR] 0·871, 95% CI 0·762–0·996; p=0·044) in patients with advanced non-small-cell lung cancer (NSCLC). To define patients benefiting most from cetuximab, we studied the association of tumour EGFR expression level with clinical outcome in FLEX study patients.
Methods
We used prospectively collected tumour EGFR expression data to generate an immunohistochemistry score for FLEX study patients on a continuous scale of 0–300. We used response data to select an outcome-based discriminatory threshold immunohistochemistry score for EGFR expression of 200. Treatment outcome was analysed in patients with low (immunohistochemistry score <200) and high (≥200 …
学术搜索中的文章
R Pirker, JR Pereira, J Von Pawel, M Krzakowski… - The lancet oncology, 2012
